stella
beta
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer — Stella
Recruiting
Back to Triple Negative Breast Cancer trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
United States
Stanford University, Stanford, California
View full record on ClinicalTrials.gov